In patients aged 60 or younger with intermediate-risk AML, primary allogeneic HCT during first complete remission was not linked with superior overall survival, compared with consolidation chemotherapy during the first complete...
Subsets of patients older than 65 with AML benefit from allogeneic stem cell transplantation and intensive chemotherapy (IT), according to a study published in Hematology. Karin Mayer, MD, and colleagues conducted a...